ペンタサイクルのトリテルペノイドイソアルボリノールの抗アディポゲン効果は,LKB1- AMPKの活性化によって媒介されます
Yesenia Arcos-Reyes1, Gildardo Rivera2, Laurence A Marchat1
1Instituto Politécnico Nacional, Escuela Nacional de Medicina y Homeopatía, Laboratorio de Biomedicina Molecular 2, México City, México.
PloS one
|September 3, 2025
まとめ
植物由来化合物であるイソアルボリノールは,脂肪細胞 (脂肪細胞) の分化を効果的に阻害し,脂質の蓄積を減少させます. この抗肥満効果は,LKB1- AMPK経路の活性化に関連しており,代謝障害に対する潜在的な治療戦略を提供します.
科学分野:
- メタボロミクス
- 分子生物学
- 薬理学について
背景:
- 肥満は慢性疾患に関連した 世界的な健康危機です
- ペンタサイクルトリテルペンのような植物代謝物は 抗肥満療法として有望です
- これらの化合物は,LKB1-AMPKを含むアディポゲネシス調節およびシグナル伝達経路を調節することができる.
研究 の 目的:
- ペンタサイクリックトリテルペンイソアルボリノールの抗アディポゲン効果を調査する.
- 3T3-L1細胞におけるアディポゲネシスに対するイソアルボリノールの作用を明らかにする.
主な方法:
- 3T3-L1前脂肪細胞の細胞培養
- アディポゲン分化と脂質蓄積の評価
- アディポゲネシスとリポゲネシスに関連する遺伝子とタンパク質発現の分析
- LKB1とAMPKのリン酸化に対するウエスタンブロット分析
主要な成果:
- イソアルボリノールは3T3- L1細胞の分化と脂質の蓄積を投与量に依存して抑制した.
- C/EBPβ,C/EBPδ,C/EBPα,PPARγ,SREBP- 1Cの重要なアディポゲンレギュレーターの発現を変化させた.
- イソアルボリノールはLKB1とAMPKのリン酸化を増加させ,リポゲン系因子ACC1,FAS,FABP4を低下させました.
結論:
- イソアルボリノールは,有意な抗アディポゲン性を持っています.
- そのメカニズムは,LKB1- AMPK経路の活性化によるもので,アディポゲネシス主調節体と脂質生成因子に影響を及ぼします.
- イソアルボリノールは肥満の管理のための潜在的な治療候補である.
関連する概念動画
cAMP-dependent Protein Kinase Pathways
6.6K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.6K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
Adrenergic Receptors: β Subtype
2.0K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.0K
GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


